|
Supplements
Educational programs require versions of browsers developed within the last 2 years.
Certain program content and other materials are issued as PDF files and require Adobe Acrobat Reader to access and print. Click here to download the latest version of the software.
Click here to read our privacy policy for supplements and educational programs.
Challenges and Opportunities in Schizophrenia Treatment
February 2013
 Based on a satellite symposium held at the annual conference of the American Academy of Clinical Psychiatrists, this supplement reviews the safety and efficacy challenges that clinicians and their adult patients with schizophrenia face when considering treatment options. The supplement also presents data from clinical trials of Latuda® (lurasidone HCl), an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia. The supplement is sponsored by Sunovion Pharmaceuticals Inc.
INDICATIONS AND USAGE
LATUDA is an atypical antipsychotic indicated for the treatment of patients with schizophrenia. Efficacy was established in five 6-week controlled studies of adult patients with schizophrenia. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
IMPORTANT INFORMATION FOR LATUDA
|
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning.
• Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
• LATUDA is not approved for the treatment of patients with dementia-related psychosis.
|
Before prescribing LATUDA, please read the full Prescribing Information, including Boxed Warning.
This supplement is sponsored by Sunovion Pharmaceuticals Inc.
It was peer reviewed by Current Psychiatry.
Download the PDF
LATUDA and  are registered trademarks of Dainippon Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. ©2013 Sunovion Pharmaceuticals Inc. All rights reserved. 2/13 LAT062-13
Challenges and Opportunities in Schizophenia Treatment:
A Focus on LATUDA
October 2011
 This educational supplement is based on a satellite symposium held at the annual conference of the American Academy of Clinical Psychiatrists in April of 2011. It presents important data from clinical trials for Latuda® (lurasidone HCl) tablets, an atypical antipsychotic agent approved for the treatment of adult patients with schizophrenia.
|
This supplement is sponsored by Sunovion Pharmaceuticals Inc.
It was peer reviewed by Current Psychiatry.
|
Full text
Download the PDF
Understanding the Complexities of Schizophrenia
October 2011
 Based on a satellite symposium held at the annual conference of the American Academy of Clinical Psychiatrists in April of 2011, this supplement provides an update on the brain abnormalities associated with schizophrenia, the possible role of genetics in the disorder, and persistent management challenges—
including treatment side effects and nonadherence. The supplement also presents data from clinical trials on an atypical antipsychotic agent approved for the treatment of adult patients with schizophrenia.
|
This supplement is sponsored by Sunovion Pharmaceuticals Inc.
It was peer reviewed by Current Psychiatry.
|
Full text
Download the PDF
 is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. ©2011 Sunovion Pharmaceuticals Inc. All rights reserved. 10/11 LUR750-11
Transcranial Magnetic Stimulation for Major Depressive Disorder: A Pragmatic Approach to Implementing TMS in a Clinical Practice
December 2010
 More than 4 million patients need a new option because they do not receive adequate benefit from antidepressant medication for their major depressive illness. NeuroStar Transcranial Magnetic Stimulation Therapy is a nonsystemic depression option available for outpatient treatment in a psychiatrist’s office. Transcranial magnetic stimulation (TMS) uses a pulsed magnet field to modulate brain cortical activity in the region of the brain associated with mood. NeuroStar TMS has been shown in clinical trials to be an effective antidepressant without the systemic side effects associated with antidepressant medication. NeuroStar TMS is the only TMS device cleared by the FDA for the treatment of adult patients with major depressive disorder (MDD) who have not benefited from prior antidepressant medication. For this supplement a panel of psychiatrists who are experts in the field of TMS was convened, and they discuss the role for TMS in the treatment of MDD and their experiences with the use of TMS in their clinical practices.
This supplement was submitted and supported by an educational grant from Neuronetics, Inc. It was peer reviewed by Current Psychiatry.
Full text
Download the PDF
Challenges in recognition, clinical management, and treatment of bipolar disorder at the interface of psychiatric medicine and primary care
November 2007
 Bipolar disorder is often mistaken by primary care providers as a major depressive episode, and is also under-recognized in psychiatric settings. Based on the insights of a panel of primary care and psychiatric experts, this supplement provides extensive practical, case-based insights into the diagnosis, management, and collaborative care of patients with bipolar disorder in a variety of settings.
Download the PDF
View the Mood Disorder Questionnaire (Read only)
|
